Académique Documents
Professionnel Documents
Culture Documents
Corporate Presentation
October 2014
OTCQB: PTLF
Safe Harbor
This document is being provided by PetLife solely for the information of those persons to whom it is
transmitted. No person in any jurisdiction may treat this document as constituting either an offer to
sell or solicitation of an offer to buy any securities in the Company. A prospective subscriber must rely
solely on the terms of and disclosure of information including important information regarding risks
and conflicts of interest contained in the Company's final offering memorandum and related
documents, the only basis on which subscriptions may be made.
Safe Harbor Statement
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: PetLife encourages
those interested in our Company to rely only on information included in our filings with the United
States Securities and Exchange Commission which can be found at www.sec.gov. Statements released
by PetLife that are not purely historical are forward-looking within the meaning of the "Safe Harbor"
provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the
company's expectations, hopes, intentions, and strategies for the future. Investors are cautioned that
forward-looking statements involve risk and uncertainties that may affect the company's business
prospects and performance. The company's actual results could differ materially from those in such
forward-looking statements. Risk factors include but are not limited to general economic, competitive,
governmental, and technological factors as discussed in the company's filings with the SEC on Forms
10-K, 10-Q, and 8-K. The Company does not undertake any responsibility to update the forwardlooking statements contained in this release.
OTCQB: PTLF
$0.85
Volume (3 month)
2,885
52 Week High/Low
$1.57/$0.16
58.0M
Float
11.0M
% Insiders
Market Cap
52%
$50M
Other
Headquarters
Beverly Hills, CA
Public Since
Website
www.PetLifepharma.com
OTCQB: PTLF
About PetLife
PetLife Pharmaceuticals (PetLife) has developed
and is launching a new generation of high-potency
veterinary oncology medications & nutraceuticals
Escozine for Pets is based on the same patented
formula of Escozine used for the treatment of
cancer in humans but is amplified through
polarization technology
Escozine for humans uses blue scorpion venom &
is currently sold as either a nutraceutical or
prescription drug in 40 countries, including the U.S.
Over 12 million dogs and cats are diagnosed with
cancer annually. Our products will be utilized as
both a preventative & treatment of cancer.
1American
Pet Products Association (2014). Pet Industry Market Size & Ownership Statistics.
OTCQB: PTLF
1American
Pet Products Association (2014). Pet Industry Market Size & Ownership Statistics.
$4.7
$2.2
Supplies/OTC Medicine
Vet Care
$22.6
$15.3
OTCQB: PTLF
Why PetLife?
Tragically, 12.5 million pet owners who leave
the vets office with a pet cancer diagnosis
annually must decide:
Escozine?
Or do nothing?
1American
Pet Products Association (2014). Pet Industry Market Size & Ownership Statistics.
OTCQB: PTLF
Medolife
Sister Company Medolife invested $10 M
over 10 years in Escozine for Humans
Research and Development
Medolife is dedicated to R&D of alternative natural products to effectively improve health at
a cellular level. Escozine containing small molecular peptides (chlorotoxin CLTX)
extracted from blue scorpion serum is an oncology therapy. Pre-clinical research
demonstrates Escozine ability to kill cancer cells in animals (UCSD Moores Cancer Center,
2012)
Markets Addressed
Since 2007, Escozine for cancer prevention & treatment has been sold in 40 countries.
Humans, dogs and cats share similar histology. PetLife signed a worldwide license to Arthur
Mikaelians IP and production patent # US 8097284 B2 and commenced operations.
OTCQB: PTLF
Escozine contains CLTX peptide extracts from Blue Scorpion venom, harvested
from scorpions at farms in the Caribbean where PetLife has significant
production capacity.
Patented polarization technology involves specific frequencies and harmonics,
to achieve a resonance between the electromagnetic frequencies and the
molecular frequency of the small molecular peptide CLTX.
Polarized Dilute Blue Scorpion Venom solution leads to more apoptosis vs. non.
See U.S. Patent 8,097,284 B2, as it pertains to Polarized Scorpion Venom
solution, and the method for producing it.
OTCQB: PTLF
Product Roadmap
Introduce a line of
Escozine for PetsTM
preventative dog and
cat treats, and an
arthritis product,
scheduled for
introduction in Q1-15.
Concurrently, apply to
US FDA in Q4-14 (ANDA)
for approval of Rx
strength versions for use
by veterinarians:
IV administered
Injectable version for
direct into tumors.
Historically, the FDA process for similar types of pet products is straightforward and
typically approved in 9 to 15 months.
OTCQB: PTLF
Venom-Based Medication
Gaining Traction & Government Support
A Science Gaining Traction and Govt Support
www.venomics-project.eu
The VENOMICS consortium is composed of 8 partners representing
5 countries (France, Spain, Portugal, Belgium and Denmark), and is a
mix of academic laboratories , SMEs and biotech firms devoted to
novel drug discovery that aims at implementing a faster and more
efficient strategy for the exploitation of venoms as a drug discovery
resource.
It has been assembled by VenomeTech, project leader, to select the
best European experts in the fields of transcriptomics, proteomics,
peptide production and drug discovery.
_________________________________________________________________________
VENOMICS: In the future, it can be envisaged that almost the full extent of the 40,000,000
biologically active molecules found in animal venoms will become available as a resource for drug
discovery.
This will offer a plethora of new opportunities in drug discovery and will permit the consortium to
undertake in-house drug development and generate licensing opportunities for pharmaceutical
companies in dire need of novel drug sources.
OTCQB: PTLF
10
OTCQB: PTLF
11
UCSD Moores Cancer Center: Pre-clinical tests in 2012 demonstrated Escozines ability to target
and kill malignant cells in animals as well as its synergy when used with traditional
chemotherapy.
Cedars Sinai Medical Center & City of Hope, CA: Scientists demonstrated Synthetic Version of
Scorpion Venom Delivers Radioactive Iodine to Malignant Brain Tumors.
Suez Canal University, Egypt: Cytotoxic and apoptotic effect of scorpion venom demonstrated in
this study by Dr. Omran.
Transmolecular received FDA approval that synthetic Chlorotoxin (CLTX) crosses blood-brain and
tissue barriers & binds preferentially to glioma cells without affecting surrounding healthy
tissue. Escozines natural CLTX - superior.
Seattle Children's Hospital: In conjunction with Prof. Fred Hutchinson at Cancer Research
Center - Seattle has re-engineered the scorpion venom protein which binds to cancer cells, and
is then joined with a fluorescent molecule "flashlight" to create a tumor paint to identify
cancer cells.
OTCQB: PTLF
12
Labiofam laboratory, Cuba: Study demonstrated that the Blue Scorpion venom causes
cell death of malignant cells and is anti inflammatory and analgesic.
Labiofam laboratory, Cuba: Dr. Mikaelian participated in an open label human study
with 8,302 patients commissioned by the Cuban pharmacological company, Labiofam. It
demonstrated Blue Scorpion venom to be therapeutically effective ranging from
improvement in quality of life to remission of malignant cancer cells across a broad
spectrum of cancer types.
OTCQB: PTLF
13
Veterinary Testimonial
Dr. Raul Jimenez - Biscayne Veterinary Center
Approximately eight months ago, my team started a medical trial treatment program for a
group of 14 dogs and 3 cats diagnosed with cancer; adding the PetLife product after either
tumoral surgical excision and/or oncology therapies. The outcome has been incredible. We
have witnessed absolutely no negative side effects using this product with our patients. The
results to date have ranged from: a.) completely slowing or halting the cancers progression
b.) tumor reduction c.) systemic cancers in remission. The positive side effects have
included: a.) all of the dogs and cats treated have regained a dramatically improved quality
of life b.) an increase in their appetite c.) a dramatic improvement in both their energy level
and mood.
I am pleased to wholeheartedly endorse PetLife as a product that should be used alone,
and/or in conjunction with other clinical therapies for pets stricken with cancer. We plan to
continue documenting our clinical data and to submit the results to our veterinary medical
community.
OTCQB: PTLF
14
Customer Testimonials
Geoff and Buddy
Golden Retriever
Small tumor called anal sac adenocarcinoma
Aggressive cancer, which is usually followed by chemo and radiation
Not a treatable cancer and surgery is only used as a band aid.
Like a gift from God, a friend told me about PetLife.
It's so easy!
Orally 3 times a day and because of his type of cancer, I also administer the solution as an
enema a few times a week.
6 months later, he is still acting happy and healthy!!
He's still acting like a puppy, and giving me lots of licks and love!!!!
Thanks PetLife!!!
Geoff
OTCQB: PTLF
15
Paccal/Kin Palladia
a VetCA1
2
5
Escozine for
Pets
7
Toxicity Level
--10
--10
0-10*
Efficacy Level
--10
--10
--4
--7
--3
$507
10
$975
10
$358
10
10
10
28
0-10*
Supportive Medication
required to control side
effects
0-10*
Cost of the Product
0-10*
Patent*
0=No 10= Yes
FDA
Registration*
0=No 10= Yes
Total Score
OTCQB: PTLF
16
Build intellectual property portfolio & leverage portfolio to introduce new products
Evaluate for use in U.S. livestock market, which suffers from high rates of cancer
OTCQB: PTLF
17
Retail
Market to distributors and brick & mortar outlets such as PetSmart and Petco
Veterinarians
Utilize specialized, vertical marketing firm to both educate and sell to the vet market
Multi-level Marketing
Partnered with a proven multi-level marketing (MLM) platform to drive affiliate sales
MLM partner will utilize an initial sales and marketing force of 100 people
Retail sales driven by infomercials range from 2 to 15 times the infomercial sales
Partner with well-known celebrity, well-respected veterinarian, to film differentiated 2 to 30 minute
infomercials on Escozine for Pets
Promotion
Media
Engage industry relevant PR firm to generate media coverage for products in general news, family,
pet and veterinarian publications, e-zines, videos and the blogosphere to communicate Escozine for
Pets features and benefits
OTCQB: PTLF
18
OTCQB: PTLF
19
PetLife Management
Arthur G. Mikaelian, Ph.D., Founder, CEO and President
Invented patented Polarization technology
Researching stress hormones (cortisol, epinephrine), master gene (ATF3) and their indirect influences on cancer
cell activity and tumor progression.
Ph.D. Biological Psychology - Vernadsky University of Biosphere Knowledge, Moscow
Strategic partners
Samson Pharmaceuticals, Commerce, CA
US FDA approved facility, manufactures PetLife products.
Aguas Vivas Laboratory, Santo Domingo, DR
Venom extraction and compound preparation
OTCQB: PTLF
20
Investment Summary
PetLife to Launch
Escozine for PetsTM
nutraceutical in Fall 2014
Highly Experienced
Industry Management
and R&D Team (Medolife)
1American
Breakthrough science
with new therapy.
Currently vets use toxic
human chemo drugs,
scaled by pets weight
Pet Products Association (2014). Pet Industry Market Size & Ownership Statistics.
Multi-channel market
strategy: Direct, PR, retail,
vet clinics, infomercial,
affiliate sales
OTCQB: PTLF
21
Contact
PetLife Pharmaceuticals, Inc.
433 N. Camden Dr.
Beverly Hills, CA 90210
T: (310) 279-5152
www.PetLifePharma.com
Sebastian Serrell-Watts
Co-founder, Executive Vice President
E: info@petlifepharma.com
Investor Relations:
MZ Group
Greg Falesnik, Senior Vice President
T: (949) 385-6449
E: greg.falesnik@mzgroup.us
OTCQB: PTLF
22